Relapsed/Refractory Multiple Myeloma: Applying Real-World Evidence to CAR T-Cell Therapy

Dr. Joshua Richter and Dr. Marco Davila examine how real-world evidence is shaping the use of CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) beyond the results of pivotal clinical trials. Referencing outcomes from studies such as CARTITUDE-4, KarMMa-3, and emerging real-world analyses, the discussion highlights that the effectiveness of CAR T-cell therapy in routine practice has remained consistent despite the inclusion of more clinically complex patients than those typically enrolled in trials. Dr. Davila emphasizes that treatment decisions should extend beyond eligibility criteria to consider patient preferences, disease characteristics, and the urgency of disease control. He also discusses the importance of recognizing patients with rapidly progressive or high-risk disease who may require expedited evaluation and treatment to avoid disease progression before infusion. The conversation underscores how integrating clinical trial findings with real-world experience helps clinicians individualize treatment sequencing and optimize outcomes for patients with RRMM.